Daphne Koller
Showing 1–4 of 4 transcripts.
- Milken Institute1h 1m
Where Is the Next Cure? | Global Conference 2024
Alice Park, Noubar Afeyan, Aloe Blacc, Daphne Koller, Samarth Kulkarni, Pablo Legorreta
Leading biotech executives and researchers are redefining the industry by shifting from chronic small-molecule management to precise, curative systems-based therapies like CRISPR and mRNA platforms. This transition, fueled by artificial intelligence and a "reverse translation" innovation model, has accelerated clinical timelines while projecting a $100 billion market for GLP-1 drugs and new organ-editing solutions. Despite regulatory hurdles and high initial costs for treatments like sickle cell gene editing, stakeholders anticipate that maturing technologies and scalable manufacturing will eventually democratize access to these transformative medical breakthroughs.
- a16z22 min
Digital Biology with insitro's Daphne Koller
In-Citro, founded by Coursera co-creator Daphne Koller, is deploying a "data factory" model that uses CRISPR-edited human pluripotent stem cells to systematically generate genetic variance data for drug discovery. The company's proprietary POSH platform and multimodal biology language models analyze hundreds of millions of cells to identify disease mechanisms and predict therapeutic interventions, effectively replacing error-prone murine testing with human-derived systems. Koller aims to deliver a first tranche of medicines to patients by the end of the decade while extending this digital biology framework to address global challenges in agriculture and environmental sustainability.
- Lex Fridman1h 12m
Daphne Koller: Biomedicine and Machine Learning | Lex Fridman Podcast #93
Daphne Koller, Lex Fridman, Andrew Ng
Stanford professor and In-Citro CEO Daphne Kohler is bridging computer science and biomedicine by developing "disease-in-a-dish" models that use induced pluripotent stem cells and CRISPR to generate high-quality data for training machine learning algorithms. This strategy aims to uncover the heterogeneous biological mechanisms behind complex conditions like Alzheimer's and schizophrenia, moving beyond the limitations of traditional animal models to identify novel gene pathways and interventions. Drawing on her background co-founding Coursera, Kohler emphasizes that while artificial general intelligence remains distant, immediate progress relies on improving model uncertainty calibration and leveraging foundational mathematics to ensure AI applications in healthcare are both robust and ethically sound.
- Milken Institute1h 16m
The Future of Higher Education in America
William Bennett, Steven Knapp, Daphne Koller, Patricia McWade, Anthony Miller, John Nelson, Bill Bennett, Tony Miller, Megan Smith, John Graff
Amidst eroding public confidence and a trillion-dollar student debt crisis, the U.S. higher education sector faces significant pressure to modernize through legislative mandates for outcome transparency and disruptive online learning models. Prominent institutions and experts like George Washington University, Georgetown University, and Udacity are testing alternative strategies ranging from fixed-tuition policies and global competency credentials to robust need-based aid programs. These responses aim to address the widening gap between academic credentials and economic reality while preparing for a future where regulations tie financial aid to institutional performance and survival.